Activity of rifabutin alone and in combination with clofazimine, kanamycin and ethambutol against Mycobacterium intracellulare infections in mice

Tubercle. 1989 Sep;70(3):201-5. doi: 10.1016/0041-3879(89)90051-2.

Abstract

Treatment of mice for 12 weeks with clofazimine or kanamycin decreased the number of organisms from lungs, liver and spleen of mice infected with Mycobacterium intracellulare N-260, compared with findings seen with rifabutin or ethambutol. Treatment with various drug combinations (rifabutin-ethambutol, rifabutin-clofazimine, rifabutin-kanamycin, rifabutin-ethambutol-clofazimine, rifabutin-ethambutol-kanamycin, and rifabutin-clofazimine-kanamycin), particularly in the presence of clofazimine, enhanced elimination of the organisms from these organs.

MeSH terms

  • Animals
  • Antitubercular Agents / therapeutic use*
  • Clofazimine / therapeutic use*
  • Drug Therapy, Combination
  • Ethambutol / therapeutic use
  • Female
  • Kanamycin / therapeutic use
  • Liver / microbiology
  • Lung / microbiology
  • Mice
  • Mice, Inbred C57BL
  • Mycobacterium avium Complex / isolation & purification
  • Mycobacterium avium-intracellulare Infection / drug therapy*
  • Rifabutin
  • Rifamycins / therapeutic use*
  • Spleen / microbiology

Substances

  • Antitubercular Agents
  • Rifamycins
  • Rifabutin
  • Kanamycin
  • Ethambutol
  • Clofazimine